DCM
IBB icon

Dialectic Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Dialectic Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,000
Closed -$3.03M – 240
2014
Q4 		$3.03M Buy
+30,000
New +$2.92M 0.57% 53

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Dialectic Capital Management's IBB Position: Q4 2016 in Review

Dialectic Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2016, closing a stake of 30,000 shares — an estimated $2.9M sold.

Dialectic Capital Management first reported a position in IBB in Q3 2016 and held it in 1 quarter. The position peaked at $2.9M in Q3 2016. 523 funds tracked by Wall St. Rank hold IBB as of Q4 2016.

  • Dialectic Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2016 after selling out during the quarter.
  • Dialectic Capital Management sold 30,000 iShares Biotechnology ETF shares in Q4 2016, an estimated $2.9M.
  • Dialectic Capital Management first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 1 quarter.
  • Dialectic Capital Management's iShares Biotechnology ETF position peaked at $2.9M in Q3 2016.
  • 523 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2016.

Based on Dialectic Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.